Alcoholic Liver Disease Clinical Trial
Official title:
Feal Mycobiome Profiling Depending on Alcoholic Liver Disease Severity.
The fecal mycobiome, which refers to the community of fungi that resides in the human gut, is an important component of the gut microbiome. Research has shown that changes in the gut microbiome, including alterations in the fecal mycobiome, may play a role in the development and progression of alcoholic liver disease (ALD).One study published in the journal Gut Microbes found that individuals with ALD had a different gut microbiome composition compared to healthy individuals, including alterations in the levels of certain fungal species. Specifically, the study found that there was an increase in the abundance of the fungal genus Saccharomyces in individuals with ALD. This is significant because Saccharomyces is known to produce ethanol, which can contribute to liver damage in individuals with ALD.Another study published in the journal PLOS One found that there were differences in the levels of fungal metabolites in the fecal samples of individuals with ALD compared to healthy individuals. Specifically, the study found that there were higher levels of certain fungal metabolites, including acetaldehyde and ethanol, in the fecal samples of individuals with ALD.These findings suggest that the fecal mycobiome may play an important role in the development and progression of ALD. Maintaining a healthy gut microbiome through a balanced diet and other lifestyle factors may be an important strategy for preventing and managing ALD, and further research into the role of the fecal mycobiome in this condition is warranted.
Fecal samples were collected prospectively from 120 participants including Healthy Control (HC=20), Alcoholic hepatitis (AH=30), alcoholic cirrhosis (AC=30), Acute-on-Chronic Liver Failure (ACLF=15), Alcoholic Hepatocellular carcinoma (AHCC=25). Mycobial DNA were isolated from collected fecal samples by using DNeasy powersoil pro kit and subjected for nuclear ribosomal RNA internal transcribed spacer (ITS) gene sequencing were performed using the MiSeq sequencer on the illumine platform and based on the phylogenetic relationship, ITS-based Mycobiome Taxonomic Profiling was performed to discovery gut mycobial compositional shift along with ALD severity progression. To discover compositional shift along with ALD severity progression, various statistical analysis method is going to be performed which includes standard mean based differential analysis such ANOVA, Principle component analysis to established the basic compositional variation in all the groups. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00708617 -
FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease
|
N/A | |
Completed |
NCT00990639 -
Effect of Candesartan in Alcoholic Liver Fibrosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04106518 -
Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
|
||
Recruiting |
NCT04666402 -
Integrated Diagnostics for Early Diagnosis of Liver Disease
|
||
Recruiting |
NCT02331745 -
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
|
Phase 4 | |
Completed |
NCT01501162 -
Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
|
Phase 4 | |
Recruiting |
NCT05895890 -
French National MICMAF Cohort
|
||
Completed |
NCT04557774 -
Cognitive Function of Alcoholic Compensated Liver Cirrhosis
|
||
Recruiting |
NCT03267069 -
Evaluating Alcohol Use in Alcoholic Liver Disease
|
||
Recruiting |
NCT03295812 -
Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)
|
N/A | |
Recruiting |
NCT05855031 -
The Liver Care Trial
|
N/A | |
Not yet recruiting |
NCT03503708 -
Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
|
N/A | |
Completed |
NCT02796469 -
Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis
|
N/A | |
Completed |
NCT02140294 -
Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease
|
N/A | |
Recruiting |
NCT03209791 -
Ethanol Induces Skeletal Muscle Autophagy
|
||
Recruiting |
NCT04400604 -
Study of Alcohol-related Liver Disease in Europe
|
||
Recruiting |
NCT04736966 -
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
|
Phase 1 | |
Completed |
NCT03402256 -
Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients
|
N/A | |
Completed |
NCT01711125 -
Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease
|
Phase 3 | |
Active, not recruiting |
NCT03863730 -
Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota
|
N/A |